Miller Financial Services’s CytomX Therapeutics CTMX Stock Holding History

Miller Financial Services’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$319K	Buy	85,000 +13,000	+18%	+$49.6K	0.26%	96
2026 Q1	$338K	Buy	72,000 +4,000	+6%	+$20.3K	0.37%	77
2025 Q4	$290K	Buy	68,000 +1,000	+1%	+$3.8K	0.34%	83
2025 Q3	$214K	Buy	67,000 +16,000	+31%	+$36K	0.25%	100
2025 Q2	$116K	Hold	51,000	–	–	0.15%	105
2025 Q1	$32.4K	Buy	51,000 +26,000	+104%	+$20.2K	0.05%	94
2024 Q4	$25.8K	Buy	+25,000	New	+$26.9K	0.02%	127

Other funds holding CTMX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Miller Financial Services's CTMX Position: Q2 2026 in Review

Miller Financial Services increased its CytomX Therapeutics (CTMX) stake by 18% in Q2 2026, buying an estimated $49.6K and bringing the position to 85,000 shares worth $319K. The position accounts for 0.26% of the portfolio, ranked #96.

Miller Financial Services first reported a position in CTMX in Q4 2024 and has held it in 7 quarters since. The position peaked at $338K in Q1 2026. 178 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

Miller Financial Services held 85,000 shares of CytomX Therapeutics worth $319K as of Q2 2026.
Miller Financial Services bought 13,000 CytomX Therapeutics shares in Q2 2026, an estimated $49.6K.
CytomX Therapeutics made up 0.26% of Miller Financial Services's portfolio in Q2 2026, its #96 holding.
Miller Financial Services first reported a position in CytomX Therapeutics in Q4 2024 and has held it in 7 quarters since.
Miller Financial Services's CytomX Therapeutics position peaked at $338K in Q1 2026.
178 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on Miller Financial Services's 13F filing for Q2 2026, filed 29 Jul 2026.